OncLive TV

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.

Zeynep Eroglu, MD, discusses the rationale for evaluating encorafenib plus binimetinib and nivolumab in BRAF V600-mutant melanoma with brain metastases.

R. Lor Randall, MD, FACS, discusses how suboptimal access to multidisciplinary, coordinated care remains a critical barrier to optimal outcomes in sarcoma.

Jessica Paulus, ScD, discusses the clinical implications of using real-world data to add an external control arm to a phase 2 study in HER2+ breast cancer.

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.

Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.

Linda R. Duska, MD, MPH, discusses the background of the phase 3 KEYNOTE-A18 trial of pembrolizumab plus chemoradiotherapy in cervical cancer.

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

Timothy R. Gershon, MD, PhD, discusses ongoing research priorities neurofibromatosis type 1–associated plexiform neurofibromas

Paolo Ghia, MD, highlights the rationale for evaluating pirtobrutinib for the treatment of patients with relapsed/refractory CLL.

Eileen M. O’Reilly, MD, discusses the potential of tumor treating fields for the treatment of patients with locally advanced pancreatic cancer.

Jens Bedke, MD, discusses findings from subgroup analyses of the phase 3 EV-302/KEYNOTE-A39 trial in untreated metastatic urothelial cancer.

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.

Martin Dietrich, MD, PhD, discusses the FDA accelerated approval of zongertinib for HER2-mutated or metastatic nonsquamous NSCLC.

Rachel E. Sanborn, MD, discusses preclinical and early clinical data supporting the use of the IB6-directed ADC sigvotatug vedotin in patients with NSCLC.

Narjust Florez, MD, discusses treatment preferences in borderline resectable NSCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Aaron C. Logan, MD, PhD, discusses the FDA approval of the obe-cel in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the 2025 Bridging the Gaps in Lung Cancer meeting.

Jyoti Malhotra, MD, MPH, discusses future research directions for sigvotatug vedotin in non–small cell lung cancer.

Janice Mehnert, MD, discusses the rationale for incorporating IL-6 receptor blockade into a combination with checkpoint inhibition for patients with advanced melanoma.

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Timothy F. Cloughesy, MD, discusses the FDA approval of dordaviprone for the treatment of patients with H3K27M-mutated diffuse midline glioma.

Rocío García-Carbonero, MD, outlines diagnostic and molecular considerations for poorly differentiated GI neuroendocrine carcinoma.

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Tina Cascone, MD, PhD, discusses of perioperative nivolumab vs placebo in patients with resectable non–small cell lung cancer.